Search

everythinglearnresearchcommunity

for

Search:↓

Thymoma may link myasthenia gravis, nail dystrophy, and alopecia areata.

Rituximab can cause skin issues, but baricitinib may help improve them.

Antibody treatments show promise for hair loss but need more research.

Scientists are still unsure what triggers the immune system to attack hair follicles in Alopecia areata.

Higher levels of MIG and IP-10 may help diagnose and monitor Alopecia Areata.

Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.

Thyroid tests may not be needed for all vitiligo and alopecia areata patients unless thyroid disease symptoms appear.

Local inflammation worsens autoimmune skin conditions by increasing antibody buildup.

Therapy lowers IgM levels in dogs with severe dermatitis but not in mild cases.

HKN-2 antibody targets specific skin and hair cells, showing keratin complexity.

Clonally expanded CD8+ T cells cause alopecia areata.

Clinicians should be aware of alternating thyroid conditions and their treatment.

Innate lymphoid cells type 1 may contribute to alopecia areata by damaging hair follicles.

A rare case of lupus linked to thymoma shows complex diagnosis and management challenges.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

JAK inhibition may help manage autoimmune conditions in Down syndrome.

Anti-Desmocollin 3 antibodies can cause pemphigus-like symptoms in mice.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Developing human skin has immune cells with memory-like features.

T cells with memory features grow in number and gather around hair follicles when there are not enough immune cells.

Targeting CD200 could be a new treatment for rheumatoid arthritis.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Advanced therapy medicinal products show promise for vitiligo treatment with fewer side effects, but affordability is a challenge.

Belimumab may cause hair loss in lupus patients.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

SIG-1451 could be a promising new treatment for atopic dermatitis.

HAT-MSCs can effectively engulf harmful microbes and particles, aiding infection treatment.

The skin produces and responds to thyroid-stimulating hormone, which is controlled by other thyroid-related hormones.

Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.